399-P: Age at Menopause Was Not Associated with Microvascular Complication in Patients with Type 2 Diabetes

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 399-P
Author(s):  
CHENGHUI ZHANG ◽  
DU RONG
2021 ◽  
Vol 9 (1) ◽  
pp. e001413
Author(s):  
Jonathan Yap ◽  
Kamalesh Anbalakan ◽  
Wan Ting Tay ◽  
Daniel Ting ◽  
Carol Yim Cheung ◽  
...  

IntroductionDiabetes mellitus is a growing public health epidemic in Asia. We examined the impact of type 2 diabetes, glycemic control and microvascular complications on mortality and cardiovascular outcomes in a multiethnic population-based cohort of Asians without prior cardiovascular disease.Research design and methodsThis was a prospective population-based cohort study in Singapore comprising participants from the three major Asian ethnic groups: Chinese, Malays and Indians, with baseline examination in 2004–2011. Participants with type 1 diabetes and those with cardiovascular disease at baseline were excluded. Type 2 diabetes, Hemoglobin A1c (HbA1c) levels and presence of microvascular complications (diabetic retinopathy and nephropathy) were defined at baseline. The primary outcome was all-cause mortality and major adverse cardiovascular events (MACEs), defined as a composite of cardiovascular mortality, myocardial infarction, stroke and revascularization, collected using a national registry.ResultsA total of 8541 subjects were included, of which 1890 had type 2 diabetes at baseline. Subjects were followed for a median of 6.4 (IQR 4.8–8.8) years. Diabetes was a significant predictor of mortality (adjusted HR 1.74, 95% CI 1.45 to 2.08, p<0.001) and MACE (adjusted HR 1.64, 95% CI 1.39 to 1.93, p<0.001). In those with diabetes, higher HbA1c levels were associated with increased MACE rates (adjusted HR (per 1% increase) 1.18, 95% CI 1.11 to 1.26, p<0.001) but not mortality (p=0.115). Subjects with two microvascular complications had significantly higher mortality and MACE compared with those with only either microvascular complication (adjusted p<0.05) and no microvascular complication (adjusted p<0.05).ConclusionDiabetes is a significant predictor of mortality and cardiovascular morbidity in Asian patients without prior cardiovascular disease. Among patients with type 2 diabetes, poorer glycemic control was associated with increased MACE but not mortality rates. Greater burden of microvascular complications identified a subset of patients with poorer outcomes.


2019 ◽  
Vol 13 (4) ◽  
pp. 301-309 ◽  
Author(s):  
Chunmei Guo ◽  
Quanman Li ◽  
Gang Tian ◽  
Yu Liu ◽  
Xizhuo Sun ◽  
...  

2019 ◽  
Vol 180 (1) ◽  
pp. 41-50 ◽  
Author(s):  
Panagiotis Anagnostis ◽  
Konstantinos Christou ◽  
Aikaterini-Maria Artzouchaltzi ◽  
Nifon K Gkekas ◽  
Nikoletta Kosmidou ◽  
...  

Objective/Design Menopausal transition has been associated with a derangement of glucose metabolism. However, it is not known if early menopause (EM, defined as age at menopause <45 years) or premature ovarian insufficiency (POI, defined as age at menopause <40 years) are associated with increased risk of type 2 diabetes mellitus (T2DM). To systematically investigate and meta-analyze the best evidence regarding the association of age at menopause with the risk of T2DM. Methods A comprehensive search was conducted in PubMed, CENTRAL and Scopus, up to January 31, 2018. Data are expressed as odds ratio (OR) with 95% confidence intervals (CI). The I 2 index was employed for heterogeneity. Results Thirteen studies were included in the qualitative and quantitative analysis (191 762 postmenopausal women, 21 664 cases with T2DM). Both women with EM and POI were at higher risk of T2DM compared with those of age at menopause of 45–55 years (OR: 1.15, 95% CI: 1.04–1.26, P = 0.003; I 2: 61%, P < 0.002 and OR: 1.50, 95% CI: 1.03–2.19, P = 0.033; I 2: 75.2%, P < 0.003), respectively). Similar associations emerged when women with EM and POI were compared with those of age at menopause >45 years (OR: 1.12, 95% CI: 1.01–1.20, P < 0.02; I 2: 78%, P < 0.001 and OR: 1.53, 95% CI: 1.03–2.27, P = 0.035; I 2: 78%, P < 0.001), respectively). Conclusions Both EM and POI are associated with increased risk of T2DM.


Diabetes Care ◽  
2012 ◽  
Vol 36 (4) ◽  
pp. 1012-1019 ◽  
Author(s):  
J. S. Brand ◽  
Y. T. van der Schouw ◽  
N. C. Onland-Moret ◽  
S. J. Sharp ◽  
K. K. Ong ◽  
...  

2021 ◽  
Author(s):  
Zhonghua Luo ◽  
Tao Li ◽  
Qingqing Gao ◽  
Yu Chen ◽  
Guangyue Su ◽  
...  

Diabetic nephropathy (DN) is the most common chronic microvascular complication of diabetes. Therefore, it is of great significance to effectively prevent and treat DN. Licochalcone A (LicA) is a flavonoid...


2020 ◽  
Author(s):  
Sai Deepika ◽  
KN Shashidhar ◽  
A. Raveesha ◽  
C. Muninarayana

Background: Increase in Diabetes Mellitus increases incidence of its Microvascular complications such as diabetic retinopathy, diabetic kidney disease (DKD), neuropathy, stroke and cardio vascular diseases (CVD). Advanced glycation end products promotes Type 2 Diabetes to its major Microvascular complication; diabetic kidney disease or diabetic nephropathy leading to increase in expression of sirtuin1; a regulatory protein mediating deacetylation of histone proteins. In addition to diet and nutrition, environmental changes may increase incidence of disorders, one such factor considered in this study is Fluoride. Objective: Estimation of Sirtuin1 in type 2 diabetes mellitus and diabetic kidney disease and interpreting the outcome by diabetic profiling of patients with controls. Participants: 150 study subjects were recruited for this cross- sectional study divided into 3groups with 50 subjects in each group. Methods: Diabetic and renal profiling was carried by fully automated analyzer available in our hospital facility, eGFR was calculated, sirtuin1 and CML were measured by ELISA, serum and urine fluoride were estimated by Ion Selective Electrode. Results: Significant differences observed in FBS, PPBS and CML of deceased with controls. Least median of sirt1 was observed in diabetic nephropathy (36.9). Also, urine and serum fluoride levels were proportionally balanced in group 1& 2 in contrast with group 3 [0.28 (0.2- 0.54) & 0.2 (0.15- 0.26)]. Conclusion: Decrease in Sirtuin1 in group 3 may be due to chronic hyperglycemia and oxidative stress in diabetes hence, further research on large cohort may aid considering sirtuin1 as a biomarker or therapeutic target in aging disorders.


Sign in / Sign up

Export Citation Format

Share Document